PROJECT ANALYSIS
It all started heRE ..
U.S. Registered Medical Institute
First U.S. Medical Institution for Multispecialty Regenerative Medicine
Worldwide Network: 130 Centers in 25 Countries in 5 Continents
Teaching Physicians with most advanced Regenerative Clinical Practices
Provide Information and Education on Regenerative Treatments
For investigational use of Adipose-Derived Stem Cells (ADSC's) for clinical process and deployment
PROJECT COMPETITIVE ANALYSIS
PARTNER must look at its strengths and weaknesses as a company, and see how we can best take advantage of the opportunities that present themselves as well as how we can mitigate the threats that could challenge our growth.
Strengths
100% American Project in Technologies, Equipment, Protocols, Procedures and Medical Science knowledge, the best in the world (approved by the International Cell Surgical Society ICSS non profit organization
Leading edge, first in class, best in class, patent 3 technologies (other US institutions offer only 1 technology)
Highly experienced, respected and strong scientific, medical, technical and executive team firmly recognized by International Society for Stem Cell Application ISSCA.
Presence in 130 Centers, 25 countries in 5 continents for Cell Surgical Network International SCN
22 IRB approved and Proprietary Protocols (others have 10-11 protocols only)
Certified Training™ (Institutional Review Board IRB programs), and Int’l Certificate for physicians and lab technicians
Protection for Physicians and Techs under our “Medical Malfunction Insurance”
Not-For-Profit Concept mitigating costs in IP, Equipment and Services
Patent portfolio covering known and future FDA regulatory and legal procedures
Researches, know-how and experience bring new therapies from lab to clinic
Rapidly navigate through the landscape of challenges and opportunities in the US and Worldwide Scroll up
Weaknesses
Not widely known, yet
FDA approvals for Stem Cell surgical practice are limited to FDA Exception No. 1271. 21 CFR 1271.15(b, and Bone Marrow SC’s
MOH Regulatory system in developing countries still in growth Scroll up
Opportunities
Brand-new medicine in practice and in medical schools
No competition. No sufficient number of legally Certified physicians
Conduct new FDA clinical trials
Application of efficacious treatment for many diseases and traumatic conditions
Remarkably LUCRATIVE Project with very positive financial returns in no time for investors
Harness power of celebrity endorsements for branding identification
Educate media, public, medical profession, Banks and clients on the superiority of our technology
Invest in Social Media & Internet building brand awareness, physicians and patients loyalty, educate public, market and promote your services
Outstanding Speakers demonstrate our Regenerative Medicine research papers at conferences, trade shows and professional association events
World-wide market with strong medical tourism traffic Scroll up
Threats
In recessionary economy
Insufficient knowledge on Regenerative Medicine and Stem Cell treatment
False allegations of unscrupulous providers of stem cell treatments that are illegal and potentially harmful as they claim using stem cell therapy, while they are injecting fat tissue filler, or PRP instead
Well-capitalized clinics make their inferior technology appear more visible and desirable
Hundreds of clinics and clinicians perform unregulated and unapproved stem cell treatments for aesthetic medicine, orthopedic, neurologic and rheumatologic conditions that poses serious potential risks to patients
Overall environment of inconsistent and miss-information on stem cells
Adverse or ineffective outcomes from other stem cell clinics can spill over to all stem cell companies
Technological espionage potential and negative media propaganda
Patent laws can change in time
Recognizing the Threats as well as the Opportunities, enables us to design and execute marketing plans that will lead your business to thrive and succeed in your country